Marksans Pharma vs Jubilant Pharmova vs Granules India: Which Stock Should You Track

Marksans Pharma vs Jubilant Pharmova vs Granules India starts with the core numbers most investors compare within the Generic and Formulation Pharma segment: market capitalisation, valuation multiples, profitability and dividend yield. Figures below are sourced as of September 2026 and will shift with daily price moves.

All three names sit in the Generic and Formulation Pharma bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses.

Click Here – Get Free Investment Predictions

Marksans Pharma, Jubilant Pharmova and Granules India: Company Overview

Marksans Pharma is a listed Indian company in the Generic and Formulation Pharma space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.

Jubilant Pharmova is a listed Indian company in the Generic and Formulation Pharma space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.

Granules India is a listed Indian company in the Generic and Formulation Pharma space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.

Marksans Pharma vs Jubilant Pharmova vs Granules India: Valuation and Profitability Snapshot

Metric	Marksans Pharma	Jubilant Pharmova	Granules India
Market Cap (approx.)	Rs 15,299 crore	Rs 16,941 crore	Rs 23,282 crore
PE Ratio (TTM)	29.36	48.21	35.15
PB Ratio	5.06	2.39	3.77
Return on Equity (ROE)	13.82%	5.62%	11.70%
EPS (TTM, Rs)	11.50	22.06	24.28
Dividend Yield	0.27%	0.47%	0.19%
Debt to Equity	0.11	0.51	0.30
Book Value per Share (Rs)	66.71	445.26	226.59

Check the Univest Screener for Live Data

On valuation, Marksans Pharma trades at a PE of 29.36 and a PB of 5.06, Jubilant Pharmova at a PE of 48.21 and a PB of 2.39, while Granules India trades at a PE of 35.15 and a PB of 3.77. On return on equity, the three post 13.82%, 5.62% and 11.70% respectively, and on dividend yield they stand at 0.27%, 0.47% and 0.19%.

Marksans Pharma vs Jubilant Pharmova vs Granules India: Latest Quarterly Results

Company	Latest Quarter Revenue	Latest Quarter Net Profit	YoY Change (Revenue)	QoQ Change (Revenue)
Marksans Pharma	Rs 866.20 crore	Rs 159.41 crore	+38.5%	-2.8%
Jubilant Pharmova	Rs 2,249.30 crore	Rs 56.40 crore	+17.6%	-2.8%
Granules India	Rs 1,479.04 crore	Rs 179.96 crore	+20.6%	-0.0%

Quarterly figures above are the most recent reported quarter for each company (Q1 FY28, quarter ended June 2026), compared with the year-ago and preceding quarter.

Download the Univest iOS App or Univest Android App to track Marksans Pharma, Jubilant Pharmova and Granules India live prices.

What Should Investors Look at Beyond These Numbers?

Beyond the metrics above, investors comparing these three generic and formulation pharma names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and any sector-specific regulatory developments, since a single-quarter snapshot can shift quickly.

Conclusion

Marksans Pharma vs Jubilant Pharmova vs Granules India highlights how differently three companies in the same generic and formulation pharma segment can score across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.

FAQs on Marksans Pharma vs Jubilant Pharmova vs Granules India

What is the market cap difference between Marksans Pharma, Jubilant Pharmova and Granules India?

Ans. As of September 2026, Marksans Pharma has a market cap of approximately Rs 15,299 crore, Jubilant Pharmova is at approximately Rs 16,941 crore, and Granules India is at approximately Rs 23,282 crore.

Which of the three has the highest PE ratio?

Ans. Among Marksans Pharma, Jubilant Pharmova and Granules India, the PE ratios stand at 29.36, 48.21 and 35.15 respectively as of September 2026.

Which of the three has the highest ROE?

Ans. Marksans Pharma, Jubilant Pharmova and Granules India post ROE of 13.82%, 5.62% and 11.70% respectively as of September 2026.

Which of these three stocks pays the highest dividend yield?

Ans. Marksans Pharma, Jubilant Pharmova and Granules India carry dividend yields of 0.27%, 0.47% and 0.19% respectively.

What is the debt to equity ratio for Marksans Pharma, Jubilant Pharmova and Granules India?

Ans. Marksans Pharma carries a debt to equity of 0.11, Jubilant Pharmova of 0.51, and Granules India of 0.30.

Which of the three trades at the highest price to book value?

Ans. Marksans Pharma, Jubilant Pharmova and Granules India trade at price to book ratios of 5.06, 2.39 and 3.77 respectively.

Is one of Marksans Pharma, Jubilant Pharmova or Granules India better than the others?

Ans. This comparison does not declare one stock better than another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor's own criteria and research.